<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TROVAN- trovafloxacin mesylate tablet, film coated </strong><br><strong>TROVAN- trovafloxacin mesylate injection, solution, concentrate </strong><br>Roerig<br></p></div>
<h1>TROVAN<span class="Sup">®</span> Tablets<br>(trovafloxacin mesylate)<br><br>TROVAN<span class="Sup">®</span> I.V.<br>(alatrofloxacin mesylate injection)<br>For Intravenous Infusion</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Boxed_Warning"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">TROVAN® HAS BEEN ASSOCIATED WITH SERIOUS <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> LEADING TO LIVER TRANSPLANTATION AND/OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. TROVAN-ASSOCIATED <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span>. <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE-EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE-  OR LIMB-THREATENING <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE. (SEE <span class="Underline"><a href="#Warnings">WARNINGS</a></span>.)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First">TROVAN is available as TROVAN Tablets (trovafloxacin mesylate) for oral administration and as TROVAN I.V. (alatrofloxacin mesylate injection), a prodrug of trovafloxacin, for intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>TROVAN Tablets</h2>
<p class="First"><span class="Bold">TROVAN Tablets</span> contain trovafloxacin mesylate, a synthetic broad-spectrum antibacterial agent for oral administration. Chemically, trovafloxacin mesylate, a fluoronaphthyridone related to the fluoroquinolone antibacterials, is (1α, 5α, 6α)-7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate. Trovafloxacin mesylate differs from other quinolone derivatives by having a 1,8-naphthyridine nucleus.</p>
<p>The chemical structure is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=DA9B26BB-D2D7-4113-A0F9-C6C2280F4875&amp;name=trovan-image01.jpg"></div>
<p>Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">15</span>F<span class="Sub">3</span>N<span class="Sub">4</span>O<span class="Sub">3</span>•CH<span class="Sub">3</span>SO<span class="Sub">3</span>H and its molecular weight is 512.46.</p>
<p>Trovafloxacin mesylate is a white to off-white powder.</p>
<p>Trovafloxacin mesylate is available in 100 mg and 200 mg (trovafloxacin equivalent) blue, film-coated tablets. TROVAN Tablets contain microcrystalline cellulose, cross-linked sodium carboxymethylcellulose and magnesium stearate. The tablet coating is a mixture of hydroxypropylcellulose, hydroxypropylmethylcellulose, titanium dioxide, polyethylene glycol and FD&amp;C blue #2 aluminum lake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>TROVAN I.V.</h2>
<p class="First"><span class="Bold">TROVAN I.V.</span> contains alatrofloxacin mesylate, the L-alanyl-L-alanyl prodrug of trovafloxacin mesylate. Chemically, alatrofloxacin mesylate is (1α, 5α, 6α)-L-alanyl-<span class="Italics">N</span>-[3-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5,8-dihydro-5-oxo-1,8-naphthyridine-2-yl]-3-azabicyclo[3.1.0]hex-6-yl]-L-alaninamide, monomethanesulfonate. It is intended for administration by intravenous infusion.</p>
<p>Following intravenous administration, the alanine substituents in alatrofloxacin are rapidly hydrolyzed <span class="Italics">in vivo</span> to yield trovafloxacin. (See <span class="Bold"><a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>The chemical structure is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=DA9B26BB-D2D7-4113-A0F9-C6C2280F4875&amp;name=trovan-image02.jpg"></div>
<p>Its empirical formula is C<span class="Sub">26</span>H<span class="Sub">25</span>F<span class="Sub">3</span>N<span class="Sub">6</span>O<span class="Sub">5</span>•CH<span class="Sub">3</span>SO<span class="Sub">3</span>H and its molecular weight is 654.62.</p>
<p>Alatrofloxacin mesylate is a white to light yellow powder.</p>
<p>TROVAN I.V. is available in 40 mL and 60 mL single use vials as a sterile, preservative-free aqueous concentrate of 5 mg trovafloxacin/mL as alatrofloxacin mesylate intended for dilution prior to intravenous administration of doses of 200 mg or 300 mg of trovafloxacin, respectively. (See <span class="Bold">HOW SUPPLIED</span>.)</p>
<p>The formulation contains Water for Injection, and may contain sodium hydroxide or hydrochloric acid for pH adjustment. The pH range for the 5 mg/mL aqueous concentrate is 3.5 to 4.3.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clinical_Pharmacology"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Absorption</h2>
<p class="First">Trovafloxacin is well-absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 88%. For comparable dosages, no dosage adjustment is necessary when switching from parenteral to oral administration (Figure 1). (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=DA9B26BB-D2D7-4113-A0F9-C6C2280F4875&amp;name=trovan-image03.jpg"></div>
<p>Figure 1. Mean trovafloxacin serum concentrations determined following 1 hour intravenous infusions of alatrofloxacin at daily doses of 200 mg (trovafloxacin equivalents) to healthy male volunteers and following daily oral administration of 200 mg trovafloxacin for 7 days to six male and six female healthy young volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The mean pharmacokinetic parameters (±SD) of trovafloxacin after single and multiple 100 mg and 200 mg oral doses and 1 hour intravenous infusions of alatrofloxacin in doses of 200 and 300 mg (trovafloxacin equivalents) appear in the chart below.</p>
<table width="100%">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="8">TROVAFLOXACIN PHARMACOKINETIC PARAMETERS</th></tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="left">C<span class="Sub">max</span><br>(µg/mL)</th>
<th class="Lrule" align="left">T<span class="Sub">max</span><br>(hrs)</th>
<th class="Lrule" align="left">AUC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(µg•h/mL)</th>
<th class="Lrule" align="left">T<span class="Sub">½</span><br>(hrs)</th>
<th class="Lrule" align="left">Vd<span class="Sub">ss</span><br>(L/Kg)</th>
<th class="Lrule" align="left">CL<br>(mL/hr/Kg)</th>
<th class="Lrule Rrule" align="left">CL<span class="Sub">r</span><br>(mL/hr/Kg)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="8">C<span class="Sub">max</span>=Maximum serum concentration; T<span class="Sub">max</span>=Time to C<span class="Sub">max</span>; AUC=Area under concentration vs. time curve; T<span class="Sub">1/2</span>=serum half-life; Vd<span class="Sub">ss</span>=Volume of distribution; Cl=Total clearance; Cl<span class="Sub">r</span>=Renal clearance</td></tr>
<tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Single dose: AUC(0–∞), multiple dose: AUC(0–24)</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>trovafloxacin equivalents</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Underline">Trovafloxacin 100 mg</span></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Single dose</td>
<td class="Lrule" align="left">1.0±0.3</td>
<td class="Lrule" align="left">0.9±0.4</td>
<td class="Lrule" align="left">11.2±2.2</td>
<td class="Lrule" align="left">  9.1</td>
<td class="Lrule" align="left">—</td>
<td class="Lrule" align="left">—</td>
<td class="Lrule Rrule" align="left">—</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Multiple dose</td>
<td class="Botrule Lrule" align="left">1.1±0.2</td>
<td class="Botrule Lrule" align="left">1.0±0.5</td>
<td class="Botrule Lrule" align="left">11.8±1.8</td>
<td class="Botrule Lrule" align="left">10.5</td>
<td class="Botrule Lrule" align="left">—</td>
<td class="Botrule Lrule" align="left">—</td>
<td class="Botrule Lrule Rrule" align="left">—</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Underline">Trovafloxacin 200 mg</span></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Single dose</td>
<td class="Lrule" align="left">2.1±0.5</td>
<td class="Lrule" align="left">1.8±0.9</td>
<td class="Lrule" align="left">26.7±7.5</td>
<td class="Lrule" align="left">  9.6</td>
<td class="Lrule" align="left">—</td>
<td class="Lrule" align="left">—</td>
<td class="Lrule Rrule" align="left">—</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Multiple dose</td>
<td class="Botrule Lrule" align="left">3.1±1.0</td>
<td class="Botrule Lrule" align="left">1.2±0.5</td>
<td class="Botrule Lrule" align="left">34.4±5.7</td>
<td class="Botrule Lrule" align="left">12.2</td>
<td class="Botrule Lrule" align="left">—</td>
<td class="Botrule Lrule" align="left">—</td>
<td class="Botrule Lrule Rrule" align="left">—</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Underline">Alatrofloxacin 200 mg<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Single dose</td>
<td class="Lrule" align="left">2.7±0.4</td>
<td class="Lrule" align="left">1.0±0.0</td>
<td class="Lrule" align="left">28.1±5.1</td>
<td class="Lrule" align="left">  9.4</td>
<td class="Lrule" align="left">1.2±0.2</td>
<td class="Lrule" align="left">93.0±17.4</td>
<td class="Lrule Rrule" align="left">6.5±3.5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Multiple dose</td>
<td class="Botrule Lrule" align="left">3.1±0.6</td>
<td class="Botrule Lrule" align="left">1.0±0.0</td>
<td class="Botrule Lrule" align="left">32.2±7.3</td>
<td class="Botrule Lrule" align="left">11.7</td>
<td class="Botrule Lrule" align="left">1.3±0.1</td>
<td class="Botrule Lrule" align="left">81.7±17.8</td>
<td class="Botrule Lrule Rrule" align="left">8.6±2.4</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Underline">Alatrofloxacin 300 mg<a href="#footnote-2" class="Sup">†</a></span></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Single dose</td>
<td class="Lrule" align="left">3.6±0.6</td>
<td class="Lrule" align="left">1.3±0.4</td>
<td class="Lrule" align="left">46.1±5.2</td>
<td class="Lrule" align="left">11.2</td>
<td class="Lrule" align="left">1.2±0.1</td>
<td class="Lrule" align="left">84.6±6.0</td>
<td class="Lrule Rrule" align="left">6.9±0.5</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Multiple dose</td>
<td class="Lrule" align="left">4.4±0.6</td>
<td class="Lrule" align="left">1.2±0.2</td>
<td class="Lrule" align="left">46.3±3.9</td>
<td class="Lrule" align="left">12.7</td>
<td class="Lrule" align="left">1.4±0.1</td>
<td class="Lrule" align="left">84.5±11.1</td>
<td class="Lrule Rrule" align="left">8.4±1.8</td>
</tr>
</tbody>
</table>
<p>Serum concentrations of trovafloxacin are dose proportional after oral administration of trovafloxacin in the dose range of 30 to 1000 mg or after intravenous administration of alatrofloxacin in the dose range of 30 to 400 mg (trovafloxacin equivalents). Steady state concentrations are achieved by the third daily oral or intravenous dose of trovafloxacin with an accumulation factor of approximately 1.3 times the single dose concentrations.</p>
<p>Oral absorption of trovafloxacin is not altered by concomitant food intake; therefore, it can be administered without regard to food.</p>
<p>The systemic exposure to trovafloxacin (AUC<span class="Sub">0–∞</span>) administered as crushed tablets via nasogastric tube into the stomach was identical to that of orally administered intact tablets. Administration of concurrent enteral feeding solutions had no effect on the absorption of trovafloxacin given via nasogastric tube into the stomach. When trovafloxacin was administered as crushed tablets into the duodenum via nasogastric tube, the AUC<span class="Sub">0–∞</span> and peak serum concentration (C<span class="Sub">max</span>) were reduced by 30% relative to the orally administered intact tablets. Time to peak serum level (T<span class="Sub">max</span>) was also decreased from 1.7 hrs to 1.1 hrs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Distribution"></a><a name="section-4.3"></a><p></p>
<h2>Distribution</h2>
<p class="First">The mean plasma protein bound fraction is approximately 76%, and is concentration-independent. Trovafloxacin is widely distributed throughout the body. Rapid distribution of trovafloxacin into tissues results in significantly higher trovafloxacin concentrations in most target tissues than in plasma or serum.</p>
<table width="85%">
<col align="left">
<col align="left">
<thead><tr class="First Last">
<th class="Lrule" align="left">Fluid or Tissue</th>
<th class="Lrule Rrule" align="left">Tissue-Fluid/Serum Ratio<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (Range)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Mean values in adults over 2–29 hours following drug administration, except individual lung tissues, which were single time points of 6 hours following drug administration</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Ratio of composite AUC(0–24) in CSF/composite AUC(0–24) in serum in 22 pediatric patients aged 1 to 12 years after 1 hour I.V. infusion of single dose alatrofloxacin (equivalent trovafloxacin dose range: 4.5–9.9 mg/kg)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="Bold">Respiratory</span></td>
<td class="Botrule Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">bronchial macrophages (multiple dose)</td>
<td class="Botrule Lrule Rrule" align="left">24.1 (9.6–41.8)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">lung mucosa</td>
<td class="Botrule Lrule Rrule" align="left">1.1 (0.7–1.5)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">lung epithelial lining fluid (multiple dose)</td>
<td class="Botrule Lrule Rrule" align="left">5.8 (1.1–17.5)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">whole lung</td>
<td class="Botrule Lrule Rrule" align="left">2.1 (0.42–5.03)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Skin, Musculoskeletal</span></td>
<td class="Botrule Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">skin</td>
<td class="Botrule Lrule Rrule" align="left">1.0 (0.20–1.88)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">subcutaneous tissue</td>
<td class="Botrule Lrule Rrule" align="left">0.4 (0.15–0.68)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid</td>
<td class="Botrule Lrule Rrule" align="left">0.7–0.9 (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>/plasma)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">skeletal muscle</td>
<td class="Botrule Lrule Rrule" align="left">1.5 (0.50–2.90)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">bone</td>
<td class="Botrule Lrule Rrule" align="left">1.0 (0.55–1.67)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Gastrointestinal</span></td>
<td class="Botrule Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">colonic tissue</td>
<td class="Botrule Lrule Rrule" align="left">0.7 (0.0–1.47)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">peritoneal fluid</td>
<td class="Botrule Lrule Rrule" align="left">0.4 (0.0–1.25)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">bile</td>
<td class="Botrule Lrule Rrule" align="left">15.4 (11.9–21.0)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Central Nervous System</span></td>
<td class="Botrule Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">cerebrospinal fluid (CSF), adults</td>
<td class="Botrule Lrule Rrule" align="left">0.25 (0.03–0.33)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">cerebrospinal fluid (CSF), children</td>
<td class="Botrule Lrule Rrule" align="left">0.28<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Reproductive</span></td>
<td class="Botrule Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">prostatic tissue</td>
<td class="Botrule Lrule Rrule" align="left">1.0 (0.5–1.6)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">cervix (multiple dose)</td>
<td class="Botrule Lrule Rrule" align="left">0.6 (0.5–0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">ovary</td>
<td class="Botrule Lrule Rrule" align="left">1.6 (0.3–2.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">fallopian tube</td>
<td class="Botrule Lrule Rrule" align="left">0.7 (0.2–1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">myometrium (multiple dose)</td>
<td class="Botrule Lrule Rrule" align="left">0.6 (0.4–0.8)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">uterus</td>
<td class="Botrule Lrule Rrule" align="left">0.6 (0.3–0.8)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">vaginal fluid (multiple dose)</td>
<td class="Lrule Rrule" align="left">4.7 (0.8–20.8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Presence in Breast Milk</h2>
<p class="First">Trovafloxacin was found in measurable concentrations in the breast milk of three lactating subjects. The average measurable breast milk concentration was 0.8 µg/mL (range: 0.3–2.1 µg/mL) after single I.V. alatrofloxacin (300 mg trovafloxacin equivalents) and repeated oral trovafloxacin (200 mg) doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>Metabolism</h2>
<p class="First">Trovafloxacin is metabolized by conjugation (the role of cytochrome P<span class="Sub">450</span> oxidative metabolism of trovafloxacin is minimal). Thirteen percent of the administered dose appears in the urine in the form of the ester glucuronide and 9% appears in the feces as the N-acetyl metabolite (2.5% of the dose is found in the serum as the active N-acetyl metabolite). Other minor metabolites (diacid, sulfamate, hydroxycarboxylic acid) have been identified in both urine and feces in small amounts (&lt;4% of the administered dose).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>Excretion</h2>
<p class="First">Approximately 50% of an oral dose is excreted unchanged (43% in the feces and 6% in the urine).</p>
<p>After multiple 200 mg doses, to healthy subjects, mean (±SD) cumulative urinary trovafloxacin concentrations were 12.1±3.4 µg/mL. With these levels of trovafloxacin in urine, crystals of trovafloxacin have not been observed in the urine of human subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.1"></a><p></p>
<h3>Geriatric</h3>
<p class="First">In adult subjects, the pharmacokinetics of trovafloxacin are not affected by age (range 19–78 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.2"></a><p></p>
<h3>Pediatric</h3>
<p class="First">Limited information is available in the pediatric population (see <span class="Bold"><a href="#Distribution">Distribution</a></span>). The pharmacokinetics of trovafloxacin have not been fully characterized in pediatric populations less than 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.3"></a><p></p>
<h3>Gender</h3>
<p class="First">There are no significant differences in trovafloxacin pharmacokinetics between males and females when differences in body weight are taken into account. After single 200 mg doses, trovafloxacin Cmax and AUC(0–∞) were 60% and 32% higher, respectively, in healthy females compared to healthy males. Following repeated daily administration of 200 mg for 7 days, the Cmax for trovafloxacin was 38% higher and AUC(0–24) was 16% higher in healthy females compared to healthy males. The clinical importance of the increases in serum levels of trovafloxacin in females has not been established. (See <span class="Bold"><a href="#Information_for_Patients">PRECAUTIONS: Information for Patients</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.4"></a><p></p>
<h3>Chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h3>
<p class="First">Following repeated administration of 100 mg for 7 days to patients with mild cirrhosis (Child-Pugh Class A), the AUC(0–24) for trovafloxacin was increased ~45% compared to matched controls. Repeated administration of 200 mg for 7 days to patients with moderate cirrhosis (Child-Pugh Class B) resulted in an increase of ~50% in AUC(0–24) compared to matched controls. There appeared to be no significant effect on trovafloxacin Cmax for either group. The oral clearance of trovafloxacin was reduced ~30% in both cirrhosis groups, which corresponded to prolongation of half life by 2–2.5 hours (25–30% increase) compared to controls. There are no data in patients with severe cirrhosis (Child-Pugh Class C). Dosage adjustment is recommended in patients with mild to moderate cirrhosis. (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">The pharmacokinetics of trovafloxacin are not affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Trovafloxacin serum concentrations are not significantly altered in subjects with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance &lt;20 mL/min), including patients on hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> Potential</h3>
<p class="First">In a study of the skin response to ultraviolet and visible radiation conducted in 48 healthy volunteers (12 per group), the minimum erythematous dose (MED) was measured for ciprofloxacin, lomefloxacin, trovafloxacin and placebo before and after drug administration for 5 days. In this study, trovafloxacin (200 mg q.d.) was shown to have a lower potential for producing delayed <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> than ciprofloxacin (500 mg b.i.d.) or lomefloxacin (400 mg q.d.), although greater than placebo. (See <span class="Bold"><a href="#Information_for_Patients">PRECAUTIONS: Information for Patients</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7.7"></a><p></p>
<h3>Drug-drug Interactions</h3>
<p class="First">The systemic availability of trovafloxacin following oral tablet administration is significantly reduced by the concomitant administration of antacids containing aluminum and magnesium salts, sucralfate, vitamins or minerals containing iron, and concomitant intravenous morphine administration.</p>
<p>Administration of trovafloxacin (300 mg p.o.) 30 minutes after administration of an antacid containing magnesium hydroxide and aluminum hydroxide resulted in reductions in systemic exposure to trovafloxacin (AUC) of 66% and peak serum concentration (Cmax) of 60%. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a>, <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Concomitant sucralfate administration (1g) with trovafloxacin 200 mg p.o. resulted in a 70% decrease in trovafloxacin systemic exposure (AUC) and a 77% reduction in peak serum concentration (Cmax).  (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a>, <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Concomitant administration of ferrous sulfate (120 mg elemental iron) with trovafloxacin 200 mg p.o. resulted in a 40% reduction in trovafloxacin systemic exposure (AUC) and a 48% decrease in trovafloxacin Cmax.  (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a>, <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Concomitant administration of intravenous morphine (0.15 mg/kg) with oral trovafloxacin (200 mg) resulted in a 36% reduction in trovafloxacin AUC and a 46% decrease in trovafloxacin Cmax. Trovafloxacin administration had no effect on the pharmacokinetics of morphine or its pharmacologically active metabolite, morphine-6-β-glucuronide.  (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a>, <a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Minor <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> that are most likely without clinical significance include calcium carbonate, omeprazole and caffeine.</p>
<p>Concomitant administration of calcium carbonate (1000 mg) with trovafloxacin 200 mg p.o. resulted in a 20% reduction in trovafloxacin AUC and a 17% reduction in peak serum trovafloxacin concentration (Cmax).</p>
<p>A 40 mg dose of omeprazole given 2 hours prior to trovafloxacin (300 mg p.o.) resulted in a 17% reduction in trovafloxacin AUC and a 17% reduction in trovafloxacin peak serum concentration (Cmax).</p>
<p>Administration of trovafloxacin (200 mg) concomitantly with caffeine (200 mg) resulted in a 17% increase in caffeine AUC and a 15% increase in caffeine Cmax. These changes in caffeine exposure are not considered clinically significant.</p>
<p>No significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were seen when TROVAN was co-administered with cimetidine, theophylline, digoxin, warfarin and cyclosporine.</p>
<p>Cimetidine co-administration (400 mg twice daily for 5 days) with trovafloxacin (200 mg p.o. daily for 3 days) resulted in changes in trovafloxacin AUC and Cmax of less than 5%.</p>
<p>Trovafloxacin (200 mg p.o. daily for 7 days) co-administration with theophylline (300 mg twice daily for 14 days) resulted in no change in theophylline AUC and Cmax.</p>
<p>Trovafloxacin (200 mg p.o. daily for 10 days) co-administration with digoxin (0.25 mg daily for 20 days) did not significantly alter systemic exposure (AUC) to digoxin or the renal clearance of digoxin.</p>
<p>Trovafloxacin (200 mg p.o. daily for 7 days) did not interfere with either the pharmacokinetics or the pharmacodynamics of warfarin (daily for 21 days).</p>
<p>Concomitant oral administration of trovafloxacin did not affect the systemic exposure (AUC) or peak plasma concentrations (Cmax) of the S or R isomers of warfarin, nor did it influence <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a></span>.)</p>
<p>Trovafloxacin (200 mg p.o. daily for 7 days) co-administration with cyclosporine (daily doses from 150–450 mg for 7 days) resulted in decreases of 10% or less in systemic exposure to cyclosporine (AUC) and in the peak blood concentrations of cyclosporine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Trovafloxacin is a fluoronaphthyridone related to the fluoroquinolones with <span class="Italics">in vitro</span> activity against a wide range of gram-negative and gram-positive aerobic, and anaerobic microorganisms. The bactericidal action of trovafloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. Mechanism of action of fluoroquinolones including trovafloxacin is different from that of penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines. Therefore, fluoroquinolones may be active against pathogens that are resistant to these antibiotics. There is no cross-resistance between trovafloxacin and the mentioned classes of antibiotics. The overall results obtained from <span class="Italics">in vitro</span> synergy studies, testing combinations of trovafloxacin with beta-lactams and aminoglycosides, indicate that synergy is <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific and not commonly encountered. This agrees with results obtained previously with other fluoroquinolones. Resistance to trovafloxacin <span class="Italics">in vitro</span> develops slowly via multiple-step mutation in a manner similar to other fluoroquinolones. Resistance to trovafloxacin <span class="Italics">in vitro</span> occurs at a general frequency of between 1×10<span class="Sup">-7</span> to 10<span class="Sup">-10</span>. Although cross-resistance has been observed between trovafloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to trovafloxacin.</p>
<p>Trovafloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#Indications_And_Usage">INDICATIONS AND USAGE</a></span> section:</p>
<p><span class="Bold">Aerobic gram-positive microorganisms</span><br><span class="Italics">Enterococcus faecalis</span> (many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are only moderately susceptible)<br><span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Streptococcus agalactiae</span><br><span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br>Viridans group streptococci</p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span><br><span class="Italics">Escherichia coli<br>Gardnerella vaginalis<br>Haemophilus influenzae<br>Klebsiella pneumoniae<br>Moraxella catarrhalis<br>Proteus mirabilis<br>Pseudomonas aeruginosa</span></p>
<p><span class="Bold">Anaerobic microorganisms</span><br><span class="Italics">Bacteroides fragilis</span><br><span class="Italics">Peptostreptococcus</span> species<br><span class="Italics">Prevotella</span> species</p>
<p><span class="Bold">Other microorganisms</span><br><span class="Italics">Chlamydia pneumoniae<br>Legionella pneumophila <br>Mycoplasma pneumoniae</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold Underline">but their clinical significance is unknown</span>.</p>
<p>Trovafloxacin exhibits <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of ≤2 µg/mL against most (90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of trovafloxacin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Bold">Aerobic gram-positive microorganisms</span><br><span class="Italics">Streptococcus pneumoniae</span> (penicillin resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span><br><span class="Italics">Citrobacter freundii<br>Enterobacter aerogenes<br>Morganella morganii<br>Proteus vulgaris</span></p>
<p><span class="Bold">Anaerobic microorganisms</span><br><span class="Italics">Bacteroides distasonis<br>Bacteroides ovatus<br>Clostridium perfringens</span></p>
<p><span class="Bold">Other microorganisms</span><br><span class="Italics">Mycoplasma hominis<br>Ureaplasma urealyticum</span></p>
<p>NOTE: <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> and <span class="Italics">Mycobacterium avium-intracellulare</span> complex organisms are commonly resistant to trovafloxacin.</p>
<p>NOTE: The activity of trovafloxacin against <span class="Italics">Treponema pallidum</span> has not been evaluated; however, other quinolones are not active against <span class="Italics">Treponema pallidum.</span> (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.9"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First"><span class="Bold">Dilution Techniques: </span>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution methods<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trovafloxacin mesylate powder. The MIC values should be interpreted according to the following criteria:</p>
<p>For testing non-fastidious aerobic organisms:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">MIC (µg/mL)</span></th>
<th align="center"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤2.0</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">   4.0</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥8.0</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>For testing <span class="Italics">Haemophilus</span> spp.<a name="footnote-reference-5" href="#footnote-5" class="Sup">1</a></p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">MIC (µg/mL)</span></th>
<th align="center"><span class="Underline">Interpretation<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any results other than "Susceptible". <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding MIC results suggestive of a "nonsusceptible" category should be submitted to a reference laboratory for further testing.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="center">≤1.0</td>
<td align="center">Susceptible (S)</td>
</tr></tbody>
</table>
<p>For testing <span class="Italics">Streptococcus</span> spp. including <span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">2</a>:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">MIC (µg/mL)</span></th>
<th align="center"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤1.0</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">   2.0</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥4.0</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trovafloxacin mesylate powder should provide the following MIC values:</p>
<table width="75%">
<col align="left">
<col align="left">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Microorganism</span></th>
<th align="left"><span class="Underline">MIC Range (µg/mL)</span></th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>This quality control range is applicable to only <span class="Italics">H. influenzae</span> ATCC 49247 tested by a microdilution procedure using HTM<span class="Sup">1</span>.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>This quality control range is applicable to only <span class="Italics">S. pneumoniae</span> ATCC 49619 tested by a microdilution procedure using cation-adjusted Mueller-Hinton broth with 2–5% lysed horse blood.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Escherichia coli</span> ATCC 25922</td>
<td align="left">0.004–0.016</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span> ATCC 29213</td>
<td align="left">0.008–0.03</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Pseudomonas aeruginosa</span> ATCC 27853</td>
<td align="left">0.25–2.0</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Enterococcus faecalis</span> ATCC 29212</td>
<td align="left">0.06–0.25</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span> ATCC 49247</td>
<td align="left">0.004–0.016</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Streptococcus pneumoniae<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></span> ATCC 49619</td>
<td align="left">0.06–0.25</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Diffusion Techniques:</span> Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with trovafloxacin mesylate equivalent to 10 µg trovafloxacin to test the susceptibility of microorganisms to trovafloxacin. </p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a trovafloxacin mesylate disk (equivalent to 10 µg trovafloxacin) should be interpreted according to the following criteria:</p>
<p>The following zone diameter interpretive criteria should be used for testing non-fastidious aerobic organisms:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">Zone Diameter (mm)</span></th>
<th align="center"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥17</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">14–16</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤13</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>For testing <span class="Italics">Haemophilus</span> spp.<a name="footnote-reference-10" href="#footnote-10" class="Sup">3</a>:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">Zone Diameter (mm)</span></th>
<th align="center"><span class="Underline">Interpretation<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></span></th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any results other than "Susceptible". <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding MIC results suggestive of a "nonsusceptible" category should be submitted to a reference laboratory for further testing.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="center">≥22</td>
<td align="center">Susceptible (S)</td>
</tr></tbody>
</table>
<p>For testing <span class="Italics">Streptococcus</span> spp. including <span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">4</a>:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">Zone Diameter (mm)</span></th>
<th align="center"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥19</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">18–16</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤15</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for trovafloxacin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the trovafloxacin mesylate equivalent to 10-µg trovafloxacin disk should provide the following zone diameters in these laboratory quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="75%">
<col align="left">
<col align="center">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Microorganism</span></th>
<th align="center"><span class="Underline">Zone Diameter Range (mm)</span></th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>This quality control limit applies to tests conducted with <span class="Italics">Haemophilus influenzae</span> ATCC 49247 using HTM<span class="Sup">2</span>.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Escherichia coli</span> ATCC 25922</td>
<td align="center">29–36</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span> ATCC 25923</td>
<td align="center">29–35</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Pseudomonas aeruginosa</span> ATCC 27853</td>
<td align="center">21–27</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></span> ATCC 49247</td>
<td align="center">32–39</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a> ATCC 49619</td>
<td align="center">25–32</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Anaerobic Techniques:</span> For anaerobic bacteria, the susceptibility to trovafloxacin as MICs can be determined by standardized test methods<span class="Sup">3</span>. The MIC values obtained should be interpreted according to the following criteria:</p>
<table width="50%">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="center"><span class="Underline">MIC (µg/mL)</span></th>
<th align="center"><span class="Underline">Interpretation</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤2.0</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">   4.0</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥8.0</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation is identical to that stated above for results using dilution techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures. Standardized trovafloxacin mesylate powder should provide the following MIC values:</p>
<table width="75%">
<col align="left">
<col align="left">
<thead><tr class="First Last">
<th align="left"><span class="Underline">Microorganism</span></th>
<th align="left"><span class="Underline">MIC<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> (µg/mL)</span></th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>kThese quality control ranges were derived from tests performed in the broth formulation of Wilkins-Chalgren agar.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Bacteroides fragilis</span> ATCC 25285</td>
<td align="left">0.125–0.5</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Bacteroides thetaiotamicron</span> ATCC 29741</td>
<td align="left">0.25–1.0</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Eubacterium lentum</span> ATCC 43055</td>
<td align="left">0.25–1.0</td>
</tr>
</tbody>
</table>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">1</a></dt>
<dd>This interpretive standard is applicable only to broth microdilution susceptibility tests with <span class="Italics">Haemophilus</span> spp. using Haemophilus Test Medium (HTM)<span class="Sup">1</span>.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">2</a></dt>
<dd>These interpretive standards are applicable only to broth microdilution susceptibility tests using cation adjusted Mueller-Hinton broth with 2–5% lysed horse blood.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">3</a></dt>
<dd>This zone diameter standard is applicable only to tests with <span class="Italics">Haemophilus</span> spp. using HTM<span class="Sup">2</span>.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">4</a></dt>
<dd>These zone diameter standards only apply to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood incubated in 5% CO<span class="Sub">2</span>.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Indications_And_Usage"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below. (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span></span> caused by <span class="Italics">Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae</span>, or <span class="Italics">Staphylococcus aureus</span>. As with other antimicrobials, where <span class="Italics">Pseudomonas aeruginosa</span> is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community acquired pneumonia</span></span> caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila,</span> or <span class="Italics">Chlamydia pneumoniae</span>.</p>
<p><span class="Bold">Complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, including post-surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Escherichia coli, Bacteroides fragilis,</span> viridans group streptococci, <span class="Italics">Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus</span> species, or <span class="Italics">Prevotella</span> species.</p>
<p><span class="Bold">Gynecologic and <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span> including endomyometritis, parametritis, septic abortion and post-partum <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Escherichia coli, Bacteroides fragilis,</span> viridans group streptococci, <span class="Italics">Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus</span> species, <span class="Italics">Prevotella</span> species, or <span class="Italics">Gardnerella vaginalis.</span></p>
<p><span class="Bold">Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4087682" conceptname="Diabetic foot">diabetic foot</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span> caused by <span class="Italics">Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli,</span> or <span class="Italics">Proteus mirabilis.</span><span class="Bold"> NOTE</span>: TROVAN has not been studied in the treatment of <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">TROVAN  is contraindicated in persons with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trovafloxacin, alatrofloxacin, quinolone antimicrobial agents or any other components of these products.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">(See boxed <span class="Bold"><a href="#Boxed_Warning">WARNING</a></span>.) <span class="Bold">TROVAN-ASSOCIATED LIVER ENZYME ABNORMALITIES, SYMPTOMATIC <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">JAUNDICE</span>, AND <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">LIVER FAILURE</span> (INCLUDING RARE REPORTS OF ACUTE <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span> WITH EOSINOPHILIC INFILTRATION, LIVER TRANSPLANTATION AND/OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>) HAVE BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE IN MEN AND WOMEN. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span>. <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE-EXPOSURE. CLINICIANS SHOULD MONITOR LIVER FUNCTION TESTS (e.g., AST, ALT, BILIRUBIN) IN TROVAN RECIPIENTS WHO DEVELOP SIGNS OR SYMPTOMS CONSISTENT WITH <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span>. CLINICIANS SHOULD CONSIDER DISCONTINUING TROVAN IN THOSE PATIENTS WHO DEVELOP LIVER FUNCTION TEST ABNORMALITIES.</span></p>
<p><span class="Bold">THE SAFETY AND EFFECTIVENESS OF TROVAFLOXACIN IN PEDIATRIC PATIENTS AND ADOLESCENTS LESS THAN 18 YEARS OF AGE, PREGNANT WOMEN, AND NURSING WOMEN HAVE NOT BEEN ESTABLISHED.</span> (See <span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS: Pediatric Use</a>, <a href="#Pregnancy">Pregnancy</a>,</span> and <span class="Bold"><a href="#Nursing_Mothers">Nursing Mothers</a></span> subsections.)</p>
<p>As with other members of the quinolone class, trovafloxacin has caused <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and/or chondrodysplasia in immature rats and dogs. The significance of these findings to humans is unknown. (See <span class="Bold"><a href="#Animal_Pharmacology">ANIMAL PHARMACOLOGY</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> have been reported in patients receiving quinolones. Quinolones may also cause central nervous system stimulation which may lead to <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. These reactions may occur following the first dose. If these reactions occur in patients receiving trovafloxacin or alatrofloxacin, the drug should be discontinued and appropriate measures instituted. (See <span class="Bold"><a href="#General">PRECAUTIONS: General,</a><a href="#Information_for_Patients">Information for Patients</a>, <a href="#Drug_Interactions">Drug Interactions</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.)</p>
<p>As with other quinolones, TROVAN should be used with caution in patients with known or suspected CNS disorders, such as severe <span class="product-label-link" type="condition" conceptid="316437" conceptname="Cerebral atherosclerosis">cerebral atherosclerosis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, and other factors that predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (See <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.)</p>
<p>Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients receiving therapy with TROVAN. These reactions may occur following the first dose. Some reactions have been accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including tongue, laryngeal, throat or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), airway obstruction (including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and other serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including generalized <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</p>
<p>Life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been reported with alatrofloxacin administration. This has occurred in patients receiving alatrofloxacin at either the recommended rate of infusion or if given more rapidly. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be potentiated with the concomitant administration of anesthetic agents. Alatrofloxacin should only be administered by slow intravenous infusion over a period of 60 minutes. Blood pressure should be monitored closely during infusion.</p>
<p>TROVAN should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.)</p>
<p>Serious and sometimes fatal events, some due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and some due to uncertain etiology, have been reported in patients receiving therapy with all antibiotics. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or severe dermatologic reactions (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>); <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>; allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> or failure; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or failure; <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, including hemolytic and aplastic; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, including <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; and/or other hematologic abnormalities.</p>
<p><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including TROVAN, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of any antibacterial agent.</p>
<p>Treatment with antibacterial agents alters the flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is the primary cause of "antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>."</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. (See <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.)</p>
<p>Although not seen in TROVAN clinical trials, ruptures of the shoulder, hand, and Achilles tendons that required surgical repair or resulted in prolonged <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> have been reported in patients receiving quinolones. TROVAN should be discontinued if the patient experiences <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon. Patients should rest and refrain from exercise until the diagnosis of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been confidently excluded. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can occur during or after therapy with quinolones.</p>
<p>Trovafloxacin has not been shown to be effective in the treatment of <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. Antimicrobial agents used in high doses for short periods of time to treat <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> may mask or delay the symptoms of incubating <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. All patients with <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> at the time of diagnosis.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="General"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Moderate to severe <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reactions have been observed in patients who are exposed to direct sunlight while receiving some drugs in this class. Therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (e.g., a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span>, etc.) occurs.</p>
<p>The safety and efficacy of TROVAN in patients with severe cirrhosis (Child-Pugh Class C) have not been studied.</p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> has been reported on therapy. Clinicians should monitor pancreatic tests in patients who develop symptoms consistent with <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> as clinically indicated.</p>
<p>Because a rapid or bolus intravenous injection may result in life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, alatrofloxacin should only be administered by slow intravenous infusion over a period of 60 minutes. Profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has also been reported in patients receiving alatrofloxacin at the recommended rate of infusion. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Intravenous_Administration">DOSAGE AND ADMINISTRATION: Intravenous Administration</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Information_for_Patients"></a><a name="section-8.2"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Patients should be advised:</p>
<ul>
<li>to discontinue therapy and to inform their physician immediately if they develop symptoms suggestive of hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stool. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</li>
<li>to inform their physician if they develop symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and/or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (See <span class="Bold"><a href="#General">PRECAUTIONS: General</a></span>.)</li>
<li>that TROVAN Tablets may be taken without regard to meals;</li>
<li>that vitamins or minerals containing iron, aluminum- or magnesium-base antacids, antacids containing citric acid buffered with sodium citrate, or sucralfate or Videx<span class="Sup">®</span>, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should be taken at least 2 hours before or 2 hours after taking TROVAN tablets. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS: Drug Interactions</a></span>.);</li>
<li>that TROVAN may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> was the most common adverse reaction reported, and for females under 45 years, it was reported significantly more frequently than in other groups. The incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may be substantially reduced if TROVAN Tablets are taken at bedtime or with food. Patients should know how they react to trovafloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.);</li>
<li>to discontinue treatment and inform their physician if they experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been confidently excluded;</li>
<li>that TROVAN may be associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following the first dose, and to discontinue the drug at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, difficulty in swallowing or breathing, any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face, tightness of the throat, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>), or other symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>.);</li>
<li>to avoid excessive sunlight or artificial ultraviolet light (e.g., tanning beds) while taking TROVAN and to discontinue therapy if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (e.g., sunburn-like reaction or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span>) occurs.</li>
<li>that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have been reported in patients taking quinolones, including trovafloxacin, and to notify their physician before taking this drug if there is a history of this condition</li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_Interactions"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Antacids, Sucralfate, and Iron: The absorption of oral trovafloxacin is significantly reduced by the concomitant administration of some antacids containing magnesium or aluminum, citric acid/sodium citrate (Bicitra<span class="Sup">®</span>), as well as sucralfate and iron (ferrous ions). These agents as well as formulations containing divalent and trivalent cations such as Videx<span class="Sup">®</span>, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should be taken at least 2 hours before or 2 hours after oral trovafloxacin administration. (See <span class="Bold"><a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>Morphine: Co-administration of intravenous morphine significantly reduces the absorption of oral trovafloxacin. Intravenous morphine should be administered at least 2 hours after oral TROVAN dosing in the fasted state and at least 4 hours after oral TROVAN is taken with food. Trovafloxacin administration had no effect on the pharmacokinetics of morphine or its metabolite, morphine-6-β-glucuronide. (See <span class="Bold"><a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>Warfarin: There have been reports during the post-marketing experience that trovafloxacin/alatrofloxacin enhance the effects of warfarin, including cases of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The mechanism for this reaction is unknown. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time, International Normalized Ratio (INR) or other suitable anticoagulation tests should be closely monitored if trovafloxacin/alatrofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Minor <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> without clinical significance have been observed with co-administration of TROVAN Tablets with caffeine, omeprazole and calcium carbonate. (See <span class="Bold"><a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>No significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with theophylline, cimetidine, digoxin, warfarin, or cyclosporine have been observed with TROVAN Tablets. (See <span class="Bold"><a href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>Alatrofloxacin should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line. (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.4"></a><p></p>
<h2>Laboratory Test Interactions</h2>
<p class="First">There are no reported laboratory test interactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">Long term studies in animals to determine the carcinogenic potential of trovafloxacin or alatrofloxacin have not been conducted. </p>
<p>TROVAN did not shorten the time to development of UV-induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in hairless albino (Skh-1) mice; thus, it was not photo co-carcinogenic in this model. These mice received oral trovafloxacin and concurrent irradiation with simulated sunlight 5 days per week for 40 weeks followed by a 12-week treatment-free observation period. The daily dose of UV radiation used in this study was approximately 30% of the minimal dose of UV radiation that would induce <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in Caucasian humans. The median time to the development of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in the hairless mice (42–43 weeks) was similar in the vehicle control group and those given 10 or 30 mg/kg of trovafloxacin daily. At a dose level of 30 mg/kg/day, the mice had skin trovafloxacin concentrations of approximately 7 µg/g. Following multiple 200 mg daily doses of trovafloxacin, the amount in human skin is estimated to be about 3 µg/g, based upon plasma concentrations measured at this dose level.</p>
<p>Trovafloxacin was not mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reversion assay or CHO/HGPRT mammalian cell gene mutation assay and it was not clastogenic in mitogen-stimulated human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or mouse bone marrow cells. A mouse micronucleus test conducted with alatrofloxacin was also negative. The positive response observed in the <span class="Italics">E. coli</span> bacterial mutagenicity assay may be due to the inhibition of DNA gyrase by trovafloxacin.</p>
<p>Trovafloxacin and alatrofloxacin did not affect the fertility of male or female rats at oral and I.V. doses of 75 mg/kg/day and 50 mg/kg/day, respectively. These doses are 15 and 10 times the recommended maximum human dose based on mg/kg or approximately 2 times based on mg/m<span class="Sup">2</span>. However, oral doses of trovafloxacin at 200 mg/kg/day (40 times the recommended maximum human dose based on mg/kg or about 6 times based on mg/m<span class="Sup">2</span>) were associated with increased preimplantation loss in rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">An increase in skeletal variations was observed in rat fetuses after daily oral 75 mg/kg maternal doses of trovafloxacin (approximately 15 times the highest recommended human dose based on mg/kg or 2 times based upon body surface area) were administered during organogenesis. However, fetal skeletal variations were not observed in rats dosed orally with 15 mg/kg trovafloxacin. Evidence of fetotoxicity (increased perinatal mortality and decreased body weights) was also observed in rats at 75 mg/kg. Daily oral doses of trovafloxacin at 45 mg/kg (approximately 9 times the highest recommended human dose based on mg/kg or 2.7 times based upon body surface area) in the rabbit were not associated with an increased incidence of fetal skeletal variations or malformations.</p>
<p>An increase in skeletal variations and malformations was observed in rat fetuses after daily intravenous doses of alatrofloxacin at ≥20 mg/kg/day (approximately 4 times the highest recommended human dose based on mg/kg or 0.6 times based upon body surface area) were administered to dams during organogenesis. In the rabbit, an increase in fetal skeletal malformations was also observed when 20 mg/kg/day (approximately equal to the highest recommended human dose based upon body surface area) of alatrofloxacin was given intravenously during the period of organogenesis. Intravenous dosing of alatrofloxacin at 6.5 mg/kg in the rat or rabbit was not associated with an increased incidence of skeletal variations or malformations. Fetotoxicity and fetal skeletal malformations have been associated with other quinolones. </p>
<p>Oral doses of trovafloxacin &gt;5mg/kg were associated with an increased gestation time in rats, and several dams at 75 mg/kg experienced uterine dystocia.</p>
<p>There are no adequate and well-controlled studies in pregnant women. TROVAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Nursing_Mothers"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Trovafloxacin is excreted in human milk and was found in measurable concentrations in the breast milk of lactating subjects. (See <span class="Bold"><a href="#Distribution">CLINICAL PHARMACOLOGY, Distribution</a></span>.)</p>
<p>Because of the potential for unknown effects from trovafloxacin in nursing infants from mothers taking trovafloxacin, a decision should be made either to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Pediatric_Use"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of trovafloxacin in pediatric patients and adolescents less than 18 years of age have not been established. Quinolones, including trovafloxacin, cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> in juvenile animals of several species. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In multiple-dose clinical trials of trovafloxacin, 27% of patients were ≥65 years of age and 12% of patients were ≥75 years of age. The overall incidence of drug-related adverse reactions, including central nervous system and gastrointestinal side effects, was less in the ≥65 year group than the other age groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Over 6000 patients have been treated with TROVAN in multidose clinical efficacy trials worldwide.</p>
<p>In TROVAN studies the majority of adverse reactions were described as mild in nature (over 90% were described as mild or moderate). TROVAN was discontinued for adverse events thought related to drug in 5% of patients (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 2.4%, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 1.9%, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 1.1%, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 1.0%).</p>
<table width="75%">
<caption><span>TROVAN Drug-Related Adverse Reactions (frequency ≥1%) in Multiple-Dose Clinical Trials</span></caption>
<col align="left" width="24%">
<col align="left" width="18%">
<col align="center" width="18%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center">200 mg oral<br>qd<br>(N=3259)</th>
<th class="Botrule Lrule" align="center">200 mg I.V.→<br>200 mg oral qd<br>(N=634)</th>
<th class="Botrule Lrule Rrule" align="center">300 mg I.V.→<br>200 mg oral qd<br>(N=623)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">11%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">4%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">8%</td>
<td class="Botrule Lrule" align="center">5%</td>
<td class="Botrule Lrule Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">5%</td>
<td class="Botrule Lrule" align="center">5%</td>
<td class="Botrule Lrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">3%</td>
<td class="Botrule Lrule" align="center">1%</td>
<td class="Botrule Lrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">1%</td>
<td class="Botrule Lrule" align="center">1%</td>
<td class="Botrule Lrule Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule" align="left">Application/</td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">injection/insertion site</td>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="center">n/a</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">reaction/</td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">&lt;1%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule Lrule" align="center">&lt;1%</td>
<td class="Botrule Lrule" align="center">2%</td>
<td class="Botrule Lrule Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> on TROVAN is generally mild, lasts for a few hours following a dose, and in most cases, resolves with continued dosing. The incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> in TROVAN patients over 65 years is 3.1% and 0.6%, respectively. (See <span class="Bold"><a href="#Information_for_Patients">PRECAUTIONS: Information for Patients</a></span>.)</p>
<p>TROVAN appears to have a low potential for <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span>. In clinical trials with TROVAN, only mild, treatment-related <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> was observed in less than 0.03% (2/7096) of patients.</p>
<p>Additional reported drug-related events in clinical trials (remotely, possibly, probably or unknown) that occurred in &lt;1% of TROVAN-treated patients are:</p>
<p><span class="Bold">APPLICATION/INJECTION/INSERTION SITE:</span> Application/injection/insertion site device complications, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Bold">AUTONOMIC NERVOUS:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, increased saliva</p>
<p><span class="Bold">CARDIOVASCULAR:</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">dizziness postural</span></p>
<p><span class="Bold">CENTRAL &amp; PERIPHERAL NERVOUS SYSTEM:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, involuntary muscle contractions, speech disorder, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4243934" conceptname="Paralysis of tongue">tongue paralysis</span>, abnormal coordination, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span></p>
<p><span class="Bold">GASTROINTESTINAL:</span> altered bowel habit, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-<span class="Italics">Clostridium difficile</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span></p>
<p><span class="Bold">ORAL CAVITY:</span> <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="27587" conceptname="Disturbance of salivary secretion">altered saliva</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span></p>
<p><span class="Bold">GENERAL/OTHER:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (bacterial, fungal), <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">alcohol intolerance</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, drug (other) toxicity/reaction, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span></p>
<p><span class="Bold">HEMATOPOIETIC:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> unspecified, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold">LIVER/BILIARY:</span> increased hepatic enzymes, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, discolored feces, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="Bold">METABOLIC/NUTRITIONAL:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Bold">MUSCULOSKELETAL:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span></p>
<p><span class="Bold">PSYCHIATRIC:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">concentration impaired</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">dreaming abnormal</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>-male, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span></p>
<p><span class="Bold">REPRODUCTIVE:</span> Female: <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>; Male: <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span></p>
<p><span class="Bold">RESPIRATORY:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span></p>
<p><span class="Bold">SKIN/APPENDAGES:</span> <span class="product-label-link" type="condition" conceptid="200169" conceptname="Pruritus ani">pruritus ani</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">dermatitis fungal</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">SPECIAL SENSES:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, conjuctival <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span></p>
<p><span class="Bold">URINARY SYSTEM:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, micturition frequency, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">renal failure acute</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal function abnormal</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span></p>
<p><span class="Bold">LABORATORY CHANGES:</span> Changes in laboratory parameters, without regard to drug relationship, occurring in ≥1% of TROVAN-treated patients were: <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span> and hematocrit; <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">increased platelets</span>; decreased and increased WBC; <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>; increased ALT (SGPT), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), and alkaline phosphatase; decreased protein and albumin; increased BUN and creatinine; decreased sodium; and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. It is not known whether these abnormalities were caused by the drug or the underlying condition being treated.</p>
<p>The incidence and magnitude of liver function abnormalities with TROVAN were the same as comparator agents except in the only study in which oral TROVAN was administered for 28 days. In this study (chronic bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>) nine percent (13/140) of TROVAN-treated patients experienced elevations of serum transaminases (AST and/or ALT) of ≥3 times the upper limit of normal. These liver function test abnormalities generally developed at the end of, or following completion of, the planned 28-day course of therapy, but were not associated with concurrent elevations of related laboratory measures of hepatic function (such as serum bilirubin, alkaline phosphatase, or lactate dehydrogenase). Patients were asymptomatic with these abnormalities, which generally returned to normal within 1–2 months after discontinuation of therapy. (See <span class="Bold"><a href="#Post_Marketing_Experience">ADVERSE REACTIONS: POST-MARKETING EXPERIENCE</a></span> subsection.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Post_Marketing_Experience"></a><a name="section-9.1"></a><p></p>
<h2>POST-MARKETING EXPERIENCE</h2>
<p class="First">Adverse reactions reported with TROVAN during the post-marketing period include:</p>
<p>GASTROINTESTINAL: symptomatic <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p>GENERAL/OTHER: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>.</p>
<p>HEMATOPOIETIC: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p>LIVER/BILIARY: symptomatic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (some patients experienced an associated peripheral <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> (including acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> with eosinophilic infiltration). TROVAN-associated liver enzyme abnormalities and/or symptomatic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred during short-term or long-term therapy. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Trovafloxacin has a low order of acute toxicity. The minimum lethal oral dose in mice and rats was 2000 mg/kg or greater. The minimum lethal I.V. dose for the prodrug, alatrofloxacin, was 50–125 mg/kg for mice and greater than 75 mg/kg for rats. Clinical signs observed included <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> and respiration, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>In the event of acute oral overdosage, the stomach should be emptied by inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or by gastric lavage. The patient should be carefully observed and given symptomatic and supportive treatment. Adequate hydration should be maintained. Trovafloxacin is not efficiently removed from the body by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_And_Administration"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage for TROVAN for the treatment of serious, life- or limb-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is described in the table below. Doses of TROVAN are administered once every 24 hours. TROVAN should not usually be administered for more than 2 weeks. It should only be administered for longer than 2 weeks if the treating physician believes the benefits to the individual patients clearly outweigh the risks of such longer-term treatment. (See boxed <span class="Bold"><a href="#Boxed_Warning">WARNING</a></span>.)</p>
<p>Oral doses should be administered at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, as well as sucralfate, citric acid buffered with sodium citrate (e.g., Bicitra<span class="Sup">®</span>), metal cations (e.g., ferrous sulfate) and Videx<span class="Sup">®</span>, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution.</p>
<p>Intravenous morphine should be administered at least 2 hours after oral TROVAN dosing in the fasted state and at least 4 hours after oral TROVAN is taken with food.</p>
<p>Patients whose therapy is started with TROVAN I.V. may be switched to TROVAN Tablets to complete the course of therapy, if deemed appropriate by the treating physician. In certain patients with serious and life- or limb-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#Indications_And_Usage">INDICATIONS AND USAGE</a></span> Section, TROVAN Tablets may be considered appropriate initial therapy, when the treating physician believes that the benefit of the product for the patient outweighs the potential risk.</p>
<p>TROVAN I.V. (alatrofloxacin mesylate injection) should only be administered by INTRAVENOUS infusion. It is not for intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.</p>
<p>Single-use vials require dilution prior to administration. (See <span class="Bold"><a href="#Preparation">PREPARATION OF ALATROFLOXACIN MESYLATE INJECTION FOR ADMINISTRATION</a></span>.)</p>
<table width="75%">
<col align="left">
<col align="left">
<col align="left">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="3">DOSAGE GUIDELINES</th></tr>
<tr class="Last">
<th class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>/LOCATION<br>AND TYPE</th>
<th class="Botrule Lrule" align="left">DAILY UNIT DOSE<br>AND ROUTE OF<br>ADMINISTRATION</th>
<th class="Botrule Lrule Rrule" align="left">TOTAL DURATION<br>(See <a href="#Warnings">WARNINGS</a>.)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>due to the designated pathogens (See <span class="Bold"><a href="#Indications_And_Usage">INDICATIONS AND USAGE</a></span>.)</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>Where the 300 mg TROVAN I.V. dose is indicated, therapy should be decreased to the 200 mg dose as soon as clinically indicated.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> (See NOTE 1 below.)</td>
<td class="Botrule Lrule" align="left">300 mg I.V.<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a>followed by 200 mg oral</td>
<td class="Botrule Lrule Rrule" align="left">10–14 days</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></td>
<td class="Botrule Lrule" align="left">200 mg oral or 200 mg I.V. followed by 200 mg oral</td>
<td class="Botrule Lrule Rrule" align="left">7–14 days</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span>, including post-surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td class="Botrule Lrule" align="left">300 mg I.V.<a href="#footnote-17" class="Sup">†</a> followed by 200 mg oral</td>
<td class="Botrule Lrule Rrule" align="left">7–14 days</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Gynecologic and <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">Pelvic Infections</span> </td>
<td class="Botrule Lrule" align="left">300 mg I.V.<a href="#footnote-17" class="Sup">†</a> followed by 200 mg oral</td>
<td class="Botrule Lrule Rrule" align="left">7–14 days</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, Complicated, including <span class="product-label-link" type="condition" conceptid="4087682" conceptname="Diabetic foot">diabetic foot</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Botrule Lrule" align="left">200 mg oral or 200 mg I.V. followed by 200 mg oral</td>
<td class="Botrule Lrule Rrule" align="left">10–14 days</td>
</tr>
</tbody>
</table>
<p>NOTE: As with other antimicrobials, where <span class="Italics">Pseudomonas aeruginosa</span> is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span>:</span> No adjustment in the dosage of TROVAN is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Trovafloxacin is eliminated primarily by biliary excretion. Trovafloxacin is not efficiently removed from the body by hemodialysis.</p>
<p><span class="Bold">CHRONIC <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASE</span> (cirrhosis):</span> The following table provides dosing guidelines for patients with mild or moderate cirrhosis (Child-Pugh Class A and B). There are no data in patients with severe cirrhosis (Child-Pugh Class C).</p>
<table width="50%">
<col align="left">
<col align="left">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="left">INDICATED DOSE (Normal hepatic function)</th>
<th class="Botrule Lrule Rrule" align="left">CHRONIC <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASE</span> DOSE</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">300 mg I.V.</td>
<td class="Botrule Lrule Rrule" align="left">200 mg I.V.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">200 mg I.V. or oral</td>
<td class="Botrule Lrule Rrule" align="left">100 mg I.V. or oral</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="Intravenous_Administration"></a><a name="section-11.1"></a><p></p>
<h2>INTRAVENOUS ADMINISTRATION</h2>
<p class="First">AFTER DILUTION WITH AN APPROPRIATE DILUENT, TROVAN I.V. SHOULD BE ADMINISTERED BY INTRAVENOUS INFUSION OVER A PERIOD OF 60 MINUTES. CAUTION: RAPID OR BOLUS INTRAVENOUS INFUSION SHOULD BE AVOIDED. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>.)</p>
<p>TROVAN I.V. is supplied in single-use vials containing a concentrated solution of alatrofloxacin mesylate in Water for Injection (equivalent of 200 mg or 300 mg as trovafloxacin). Each mL contains alatrofloxacin mesylate equivalent to 5 mg trovafloxacin. (See <span class="Bold">HOW SUPPLIED</span> for container sizes.) THESE TROVAN I.V. SINGLE-USE VIALS MUST BE FURTHER DILUTED WITH AN APPROPRIATE SOLUTION PRIOR TO INTRAVENOUS ADMINISTRATION. This parenteral drug product should be inspected visually for discoloration and particulate matter prior to dilution and administration. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final parenteral solution.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Preparation"></a><a name="section-11.1.1"></a><p></p>
<h3>PREPARATION OF ALATROFLOXACIN MESYLATE INJECTION FOR ADMINISTRATION</h3>
<p class="First">The intravenous dose should be prepared by aseptically withdrawing the appropriate volume of concentrate from the vials of TROVAN I.V. This should be diluted with a suitable intravenous solution to a final concentration of 1–2 mg/mL. (See<span class="Bold"><a href="#Compatible">Compatible Intravenous Solutions</a></span>.) The resulting solution should be infused over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place.</p>
<p>Since the vials are for single-use only, any unused portion should be discarded.</p>
<p>Since only limited data are available on the compatibility of alatrofloxacin intravenous injection with other intravenous substances, additives or other medications should not be added to TROVAN I.V. in single-use vials or infused simultaneously through the same intravenous line.</p>
<p>If the same intravenous line is used for sequential infusion of several different drugs, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after infusion of TROVAN I.V. with an infusion solution compatible with TROVAN I.V. and with any other drug(s) administered via this common line.</p>
<p>If TROVAN I.V. is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each drug.</p>
<p>The desired dosage of TROVAN I.V. may be prepared according to the following chart:</p>
<table width="75%">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="center">DOSAGE STRENGTH (mg)<br>(trovafloxacin equivalent)</th>
<th class="Botrule Lrule" align="center">VOLUME TO WITHDRAW<br>(mL)</th>
<th class="Botrule Lrule" align="center">DILUENT VOLUME<br>(mL)</th>
<th class="Botrule Lrule" align="center">TOTAL VOLUME<br>(mL</th>
<th class="Botrule Lrule Rrule" align="center">INFUSION CONC<br>(mg/mL)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">100 mg</td>
<td class="Botrule Lrule" align="center">20</td>
<td class="Botrule Lrule" align="center">30</td>
<td class="Botrule Lrule" align="center">50 </td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">100 mg</td>
<td class="Botrule Lrule" align="center">20</td>
<td class="Botrule Lrule" align="center">80</td>
<td class="Botrule Lrule" align="center">100 </td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">200 mg</td>
<td class="Botrule Lrule" align="center">40</td>
<td class="Botrule Lrule" align="center">60</td>
<td class="Botrule Lrule" align="center">100 </td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">200 mg</td>
<td class="Botrule Lrule" align="center">40</td>
<td class="Botrule Lrule" align="center">160</td>
<td class="Botrule Lrule" align="center">200 </td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">300 mg</td>
<td class="Botrule Lrule" align="center">60</td>
<td class="Botrule Lrule" align="center">90</td>
<td class="Botrule Lrule" align="center">150 </td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">300 mg</td>
<td class="Botrule Lrule" align="center">60</td>
<td class="Botrule Lrule" align="center">240</td>
<td class="Botrule Lrule" align="center">300 </td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
</tbody>
</table>
<p>For example, to prepare a 200 mg dose at an infusion concentration of 2 mg/mL (as trovafloxacin), 40 mL of TROVAN I.V. is withdrawn from a vial and diluted with 60 mL of a compatible intravenous fluid to produce a total infusion solution volume of 100 mL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Compatible"></a><a name="section-11.1.1.1"></a><p></p>
<h4>Compatible Intravenous Solutions</h4>
<p class="First">5% Dextrose Injection, USP<br>0.45% Sodium Chloride Injection, USP<br>5% Dextrose and 0.45% Sodium Chloride Injection, USP<br>5% Dextrose and 0.2% Sodium Chloride Injection, USP<br>Lactated Ringer's and 5% Dextrose Injection, USP</p>
<p><span class="Bold">TROVAN I.V. should not be diluted with 0.9% Sodium Chloride Injection, USP (normal saline), alone or in combination with other diluents. A precipitate may form under these conditions. In addition, TROVAN I.V. should not be diluted with Lactated Ringer's, USP.</span></p>
<p>Normal saline, 0.9% Sodium Chloride Injection, USP can be used for <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> I.V. lines prior to or after administration of TROVAN I.V.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1.2"></a><p></p>
<h4>Stability of TROVAN I.V. as Supplied</h4>
<p class="First">When stored under recommended conditions, TROVAN I.V., as supplied in 40 mL or 60 mL vials, is stable through the expiration date printed on the label.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1.3"></a><p></p>
<h4>Stability of TROVAN I.V. Following Dilution</h4>
<p class="First">TROVAN I.V., when diluted with compatible intravenous solutions to concentrations of 0.5 to 2.0 mg/mL (as trovafloxacin), is physically and chemically stable for up to 7 days when refrigerated or up to 3 days at room temperature stored in glass bottles or plastic (PVC type) intravenous containers.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Trovan Tablets and Injection are being distributed only to hospitals and long term nursing care facilities for patients initiating therapy in these facilities</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Tablets</h2>
<p class="First">TROVAN (trovafloxacin mesylate) Tablets are available as blue, film-coated tablets. The 100 mg tablets are round and contain trovafloxacin mesylate equivalent to 100 mg trovafloxacin. The 200 mg tablets are modified oval-shaped and contain trovafloxacin mesylate equivalent to 200 mg trovafloxacin.</p>
<p>TROVAN Tablets are packaged and in unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> strips in the following configurations:</p>
<p>100-mg tablets: color: blue; shape: round; debossing: "PFIZER" on one side and "378" on the other<br>  Bottles of 30 (NDC 0049-3780-30)<br>  Unit Dose/40 tablets (NDC 0049-3780-43)</p>
<p>200-mg tablets: color: blue; shape: modified oval; debossing: "PFIZER" on one side and "379" on the other<br>  Bottles of 30 (NDC 0049-3790-30)<br>  Unit Dose/40 tablets (NDC 0049-3790-43)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<h3>Storage</h3>
<p class="First">TROVAN Tablets should be stored at 15°C to 30°C (59°F to 86°F) in airtight containers (USP).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>Injection</h2>
<p class="First">TROVAN is also available for intravenous administration as the prodrug, TROVAN I.V. (alatrofloxacin mesylate injection), in the following configurations:</p>
<p>Single-use vials containing a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow concentrated solution of alatrofloxacin mesylate equivalent to 5 mg trovafloxacin/mL.</p>
<p>  5 mg/mL, 40 mL, 200 mg<br>  Unit dose package (NDC 0049-3890-28)</p>
<p>  5 mg/mL, 60 mL, 300 mg<br>  Unit dose package (NDC 0049-3900-28)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<h3>Storage</h3>
<p class="First">TROVAN I.V. should be stored at 15°C to 30°C (59°F to 86°F). Protect From Light. Do Not Freeze.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Animal_Pharmacology"></a><a name="section-13"></a><p></p>
<h1>ANIMAL PHARMACOLOGY</h1>
<p class="First">Quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals.</p>
<p><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span> and chondrodysplasia were observed in immature animals given trovafloxacin. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
<p>At doses from 10 to 15 times the human dose based on mg/kg or approximately 3 to 5 times based on mg/m<span class="Sup">2</span>, trovafloxacin has been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature rats and dogs. In addition, these drugs are associated with an increased incidence of chondrodysplasia in rats compared to controls. There is no evidence of arthropathies in fully mature rats and dogs at doses from 40 or 10 times the human dose based on mg/kg or approximately 5 times based on mg/m<span class="Sup">2</span> for a 6 month exposure period.</p>
<p>Unlike some other members of the quinolone class, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and ocular toxicity were not observed in chronic safety studies with rats or dogs with either trovafloxacin or its prodrug, alatrofloxacin.</p>
<p>Quinolones have been reported to have proconvulsant activity that is exacerbated with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDS). Neither trovafloxacin administered orally at 500 mg/kg, nor alatrofloxacin administered intravenously at 75 mg/kg, showed an increase in measures of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity in mice at doses when used in combination with the active metabolite of the NSAID, fenbufen.</p>
<p>As with other members of the quinolone class, trovafloxacin at doses 5 to 10 times the human dose based on mg/kg or 1 to 5 times the human dose based on mg/m<span class="Sup">2</span> produces testicular degeneration in rats and dogs dosed for 6 months.</p>
<p>At a dose of trovafloxacin 10 times the highest human dose based on mg/kg or approximately 5 times based on mg/m<span class="Sup">2</span>, elevated liver enzyme levels which correlated with centrilobular hepatocellular vacuolar degeneration and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> were observed in dogs in a 6 month study. A subsequent study demonstrated reversibility of these effects when trovafloxacin was discontinued.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2>Hospitalized <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></h2>
<p class="First">Adult patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>, requiring hospitalization and initial intravenous therapy, participated in two randomized, multicenter, double-blind, double-dummy trials. The first trial compared intravenous alatrofloxacin (200 mg once daily for 2 to 7 days) followed by oral trovafloxacin (200 mg once daily) for a total of 7 to 14 days of therapy to intravenous ciprofloxacin (400 mg BID) plus ampicillin (500 mg QID) for 2 to 7 days followed by oral ciprofloxacin (500 mg BID) plus amoxicillin (500 mg TID) for a total of 7 to 14 days of therapy. The second study compared intravenous alatrofloxacin (200 mg once daily for 2 to 7 days) followed by oral trovafloxacin (200 mg once daily) for a total of 7 to 14 days of therapy to intravenous ceftriaxone (1000 mg once daily for 2 to 7 days) followed by oral cefpodoxime (400 mg BID) for 7 to 14 days of total therapy with optional blinded erythromycin added to the ceftriaxone/cefpodoxime arm if an <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">atypical pneumonia</span> was suspected.</p>
<p>The clinical success rate (cure + improvement with no need for further antibiotic therapy) at the End of Treatment was 90% (311/346) and 90% (325/363) for TROVAN and the comparator agents, respectively. The clinical success rate at the End of Study (Day 30) was 86% (256/299) and 85% (283/334) for TROVAN and the comparator agents, respectively. All cause mortality (Day 1–35) was 2.45% (10/408) on TROVAN and 5.45% (23/422) on the comparator agents.</p>
<p>The following outcomes are the clinical success rates for the clinically evaluable patient groups by pathogen in these two studies:</p>
<table width="75%">
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">End of Treatment</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">End of Study</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left">Pathogen</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule" align="center">Comparators</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule Rrule" align="center">Comparators</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="Italics">S. pneumoniae</span></td>
<td class="Botrule Lrule" align="center">89% (63/71)</td>
<td class="Botrule Lrule" align="center">95% (62/65)</td>
<td class="Botrule Lrule" align="center">87% (55/63)</td>
<td class="Botrule Lrule Rrule" align="center">91% (50/55)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">H. influenzae</span></td>
<td class="Botrule Lrule" align="center">97% (35/36)</td>
<td class="Botrule Lrule" align="center">94% (46/49)</td>
<td class="Botrule Lrule" align="center">90% (28/31)</td>
<td class="Botrule Lrule Rrule" align="center">94% (44/47)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">M. catarrhalis</span></td>
<td class="Botrule Lrule" align="center">100% (8/8)</td>
<td class="Botrule Lrule" align="center">100% (4/4)</td>
<td class="Botrule Lrule" align="center">100% (6/6)</td>
<td class="Botrule Lrule Rrule" align="center">100% (4/4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">S. aureus</span></td>
<td class="Botrule Lrule" align="center">100% (8/8)</td>
<td class="Botrule Lrule" align="center">93% (13/14)</td>
<td class="Botrule Lrule" align="center">100% (6/6)</td>
<td class="Botrule Lrule Rrule" align="center">91% (10/11)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">K. pneumoniae</span></td>
<td class="Botrule Lrule" align="center">100% (3/3)</td>
<td class="Botrule Lrule" align="center">89% (8/9)</td>
<td class="Botrule Lrule" align="center">100% (3/3)</td>
<td class="Botrule Lrule Rrule" align="center">86% (6/7)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">L. pneumophila</span></td>
<td class="Botrule Lrule" align="center">77% (10/13)</td>
<td class="Botrule Lrule" align="center">86% (12/14)</td>
<td class="Botrule Lrule" align="center">75% (9/12)</td>
<td class="Botrule Lrule Rrule" align="center">86% (12/14)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">M. pneumoniae</span></td>
<td class="Botrule Lrule" align="center">100% (20/20)</td>
<td class="Botrule Lrule" align="center">87% (13/15)</td>
<td class="Botrule Lrule" align="center">94% (17/18)</td>
<td class="Botrule Lrule Rrule" align="center">79% (11/14)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left"><span class="Italics">C. pneumoniae</span></td>
<td class="Botrule Lrule" align="center">75% (6/8)</td>
<td class="Botrule Lrule" align="center">100% (18/18)</td>
<td class="Botrule Lrule" align="center">67% (4/6)</td>
<td class="Botrule Lrule Rrule" align="center">94% (16/17)</td>
</tr>
</tbody>
</table>
<p>Of the above patients with clinical failure at end of treatment or study, only one alatrofloxacin patient (<span class="Italics">H. influenzae </span>+ <span class="Italics">S. pneumoniae</span>) and one ceftriaxone + erythromycin patient (<span class="Italics">Legionella</span>) had a microbiologically confirmed persistent pathogen at the time of failure with no emergence of resistance in either study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First">Adult patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> participated in a randomized, multicenter, double-blind, double-dummy trial comparing intravenous alatrofloxacin (300 mg once daily for 2 to 7 days) followed by oral trovafloxacin (200 mg once daily) for a total of 7 to 14 days of therapy to intravenous ciprofloxacin (400 mg BID) for 2 to 7 days followed by oral ciprofloxacin (750 mg BID) for a total of 7 to 14 days of therapy with optional blinded clindamycin or metronidazole added to the ciprofloxacin arm if an anaerobic <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> was suspected. In subjects with documented <span class="product-label-link" type="condition" conceptid="438064" conceptname="Bacterial infection due to Pseudomonas">Pseudomonas infection</span> or methicillin-resistant <span class="Italics">S. aureus</span>, aztreonam or vancomycin, respectively, could have been added to either treatment regimen.</p>
<p>The clinical success rate (cure + improvement with no need for further antibiotic therapy) at the End of Treatment was 77% (68/88) and 78% (79/101) for TROVAN and ciprofloxacin, respectively. The clinical success rate at the End of Study (Day 30) was 69% (50/72) and 68% (54/79) for TROVAN and ciprofloxacin, respectively.</p>
<p>The following outcomes are the clinical success rates for the clinically evaluable patient groups by pathogen:</p>
<table width="75%">
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">End of Treatment</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">End of Study</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left">Pathogen</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule" align="center">Ciprofloxacin</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule Rrule" align="center">Ciprofloxacin</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="Italics">P. aeruginosa</span></td>
<td class="Botrule Lrule" align="center">67% (10/15)</td>
<td class="Botrule Lrule" align="center">55% (6/11)</td>
<td class="Botrule Lrule" align="center">62% (8/13)</td>
<td class="Botrule Lrule Rrule" align="center">25% (2/8)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">H. influenzae</span></td>
<td class="Botrule Lrule" align="center">88% (7/8)</td>
<td class="Botrule Lrule" align="center">89% (8/9)</td>
<td class="Botrule Lrule" align="center">83% (5/6)</td>
<td class="Botrule Lrule Rrule" align="center">86% (6/7)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">E. coli</span></td>
<td class="Botrule Lrule" align="center">71% (5/7)</td>
<td class="Botrule Lrule" align="center">80% (4/5))</td>
<td class="Botrule Lrule" align="center">50% (3/6)</td>
<td class="Botrule Lrule Rrule" align="center">80% (4/5)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left"><span class="Italics">S. aureus</span></td>
<td class="Botrule Lrule" align="center">64% (7/11)</td>
<td class="Botrule Lrule" align="center">80% (8/10)</td>
<td class="Botrule Lrule" align="center">50% (4/8)</td>
<td class="Botrule Lrule Rrule" align="center">67% (4/6)</td>
</tr>
</tbody>
</table>
<p>Of the above patients with clinical failure at end of treatment or study, 2 alatrofloxacin patients (<span class="Italics">S. aureus, P. aeruginosa</span>) and 4 ciprofloxacin patients (all <span class="Italics">P. aeruginosa</span>) had a microbiologically confirmed persistent pathogen at the time of failure. Three of the 4 ciprofloxacin patients with clinical failure and persistence had emergence of resistance with none on alatrofloxacin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<h2>Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></h2>
<p class="First">Patients hospitalized with clinically documented, complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, including post-surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, participated in a randomized, double-blind, multicenter trial comparing intravenous alatrofloxacin (300 mg once daily) followed by oral trovafloxacin (200 mg once daily) to intravenous imipenem/cilastatin (1g q8h) followed by oral amoxicillin/clavulanic acid (500 mg TID) for a maximum of 14 days of therapy. The clinical success rate (cure + improvement) at the End of Treatment was 88% (136/155) and 86% (122/142) for alatrofloxacin→trovafloxacin and imipenem/cilastatin→amoxicillin/clavulanic acid, respectively. The clinical success rate at the End of Study (Day 30) was 83% (129/156) and 84% (127/152) for alatrofloxacin→trovafloxacin and imipenem/cilastatin→amoxicillin/clavulanic acid, respectively.</p>
<p>The following are the clinical success rates for the clinically evaluable patient groups by pathogen:</p>
<table width="75%">
<col align="left" width="25%">
<col align="center" width="17%">
<col align="center" width="20%">
<col align="center" width="18%">
<col align="center" width="20%">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">End of Treatment</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">End of Study</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left">Pathogen</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule" align="center">Imipenem/Cila Amox/Clav</th>
<th class="Botrule Lrule" align="center">TROVAN</th>
<th class="Botrule Lrule Rrule" align="center">Imipenem/Cila Amox/Clav</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="Italics">E. coli</span></td>
<td class="Botrule Lrule" align="center">94% (72/77)</td>
<td class="Botrule Lrule" align="center">90% (52/58)</td>
<td class="Botrule Lrule" align="center">86% (66/77)</td>
<td class="Botrule Lrule Rrule" align="center">86% (51/59)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">Bacteroides fragilis</span></td>
<td class="Botrule Lrule" align="center">97% (30/31)</td>
<td class="Botrule Lrule" align="center">82% (28/34)</td>
<td class="Botrule Lrule" align="center">84% (26/31)</td>
<td class="Botrule Lrule Rrule" align="center">75% (27/36)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">viridans group streptococci</td>
<td class="Botrule Lrule" align="center">90% (18/20)</td>
<td class="Botrule Lrule" align="center">83% (19/23)</td>
<td class="Botrule Lrule" align="center">90% (18/20)</td>
<td class="Botrule Lrule Rrule" align="center">78% (18/23)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td class="Botrule Lrule" align="center">94% (15/16)</td>
<td class="Botrule Lrule" align="center">82% (14/17)</td>
<td class="Botrule Lrule" align="center">88% (14/16)</td>
<td class="Botrule Lrule Rrule" align="center">83% (15/18)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">Klebsiella pneumoniae</span></td>
<td class="Botrule Lrule" align="center">80% (12/15)</td>
<td class="Botrule Lrule" align="center">71% (10/14)</td>
<td class="Botrule Lrule" align="center">67% (10/15)</td>
<td class="Botrule Lrule Rrule" align="center">71% (10/14)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">
<span class="Italics">Peptostreptococcus</span> spp.</td>
<td class="Botrule Lrule" align="center">86% (12/14)</td>
<td class="Botrule Lrule" align="center">88% (7/8)</td>
<td class="Botrule Lrule" align="center">79% (11/14)</td>
<td class="Botrule Lrule Rrule" align="center">75% (6/8)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">
<span class="Italics">Prevotella</span> spp.</td>
<td class="Botrule Lrule" align="center">77% (10/13)</td>
<td class="Botrule Lrule" align="center">50% (2/4)</td>
<td class="Botrule Lrule" align="center">77% (10/13)</td>
<td class="Botrule Lrule Rrule" align="center">60% (3/5)</td>
</tr>
</tbody>
</table>
<p>Of patients with a baseline pathogen and a clinical response of failure at the End of Study, 9 of 26 on TROVAN and 10 of 21 on imipenem/cilastatin had microbiologically-confirmed persistence of the baseline pathogen with no emergence of resistance in either group.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-15"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically –
 Fourth Edition; Approved Standard, NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, Wayne, PA, January, 1997.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests – Sixth Edition; Approved Standard, NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January, 1997.</li>
<li>National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria – Fourth Edition; Approved Standard, NCCLS Document M11-A4, Vol. 17, No. 22, NCCLS, Wayne, PA, December, 1997.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=DA9B26BB-D2D7-4113-A0F9-C6C2280F4875&amp;name=trovan-image04.jpg"></div>
<p>70-5328-00-6<br>April 2000</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TROVAN 		
					</strong><br><span class="contentTableReg">trovafloxacin mesylate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0049-3780</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trovafloxacin mesylate</strong> (trovafloxacin) </td>
<td class="formItem"></td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cross linked sodium carboxymethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxypropylmethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue #2 aluminum lake</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;378</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-3780-30</td>
<td class="formItem">30  in 01 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0049-3780-43</td>
<td class="formItem">40  in 01 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TROVAN 		
					</strong><br><span class="contentTableReg">trovafloxacin mesylate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0049-3790</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trovafloxacin mesylate</strong> (trovafloxacin) </td>
<td class="formItem"></td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cross linked sodium carboxymethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxypropylmethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue #2 aluminum lake</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;379</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-3790-30</td>
<td class="formItem">30  in 01 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0049-3790-43</td>
<td class="formItem">40  in 01 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TROVAN 		
					</strong><br><span class="contentTableReg">trovafloxacin mesylate injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0049-3890</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trovafloxacin mesylate</strong> (trovafloxacin) </td>
<td class="formItem"></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-3890-28</td>
<td class="formItem">40 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TROVAN 		
					</strong><br><span class="contentTableReg">trovafloxacin mesylate injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC: 0049-3900</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trovafloxacin mesylate</strong> (trovafloxacin) </td>
<td class="formItem"></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0049-3900-28</td>
<td class="formItem">60 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roerig</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>DFF1F954-C69D-672C-0802-8559DB322C6F</div>
<div>Set id: DA9B26BB-D2D7-4113-A0F9-C6C2280F4875</div>
<div>Version: 1</div>
<div>Effective Time: 20060206</div>
</div>
</div> <div class="DistributorName">Roerig</div></p>
</body></html>
